Monday, March 2, 2026 3/2/2026

Illuminating understudied druggable proteins using pan-cancer proteogenomics data

Award Number: U01CA271247
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/26/2022
PERIOD OF PERFORMANCE END DATE: 06/30/2025

Group Awards By:

View Award Description

Illuminating understudied druggable proteins using pan-cancer proteogenomics data - Project Summary Proteins in the families of kinases, G protein coupled receptors, and ion channels frequently contribute to disease pathogenesis and are good candidates for the development of therapeutics. In fact, 41% of the FDA- approved drugs target proteins in these families. However, each of these protein families has a number of members about which very little is known. Better understanding of these ‘dark’ members may pave the way to new methods for treating diseases. Utilizing existing large omics datasets can be a great starting point to generate new hypotheses on the function and phenotype association of the understudied proteins. Recently, the NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) program has characterized over 1,000 primary tumors covering 10 cancer types using multiple omics platforms. While previous large-scale omics datasets have focused on genomic and transcriptomic data, the CPTAC data also integrate mass spectrometry (MS)-based proteomics and phosphoproteomics. Published studies by our colleagues and us in the CPTAC consortium have demonstrated the value of these proteogenomics datasets as a comprehensive resource for reinforcing existing knowledge, identifying new biological insights, and generating therapeutic hypotheses. The goal of this application is to illuminate understudied druggable proteins using CPTAC pan-cancer proteogenomics data. We will achieve this goal by addressing two specific Aims. Aim 1 is built upon our established multi-omics data analysis portal LinkedOmics. We will extend LinkedOmics into a knowledgebase, LinkedOmicsKB, in which information derived from harmonized CPTAC pan-cancer proteogenomics data will be organized into gene- centric web pages with easily browsable sections and effective visualizations. Aim 2 is based on our previous report that protein profiling data is much more closely aligned with gene function than mRNA profiling data. We will use CPTAC pan-cancer proteomics data to make function predictions for the understudied druggable proteins, followed by experimental validation of selected predictions. Data, visualization, and prediction results from both Aims will be integrated into Pharos, the knowledge portal of the Illuminating the Druggable Genome (IDG) program, to accelerate our understanding of IDG-eligible understudied proteins.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2023	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Trans-NIH Research Support	000	2	11/18/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Trans-NIH Research Support	000	2	1/24/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $480,000 )
2023	2023	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Trans-NIH Research Support	000	2	7/31/2023	NON-COMPETING CONTINUATION	$480,000
														Subtotal = $480,000

Issue Date FY: 2022 ( Subtotal = $475,200 )
2022	2022	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Trans-NIH Research Support	000	1	7/26/2022	NEW	$475,200
														Subtotal = $475,200

Grand Total All Awards = $955,200

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Illuminating understudied druggable proteins using pan-cancer proteogenomics data

Award Number: U01CA271247

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/26/2022

PERIOD OF PERFORMANCE END DATE: 06/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer